Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Vildagliptin/Metformin FCT vs Galvus Met in Healthy Thai Volunteers
NCT06244407Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- May 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of vildagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by International Bio Service. Primary endpoint: Plasma Area Under the Curve (0 to 36hr). Planned start May 2024; status: not yet recruiting.
02
Drugs
vildagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06244407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06244407.